Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM). In this review article, we discuss the mechanistic and clinical s...

Full description

Bibliographic Details
Main Authors: Pierre Gourdy, Patrice Darmon, François Dievart, Jean-Michel Halimi, Bruno Guerci
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Cardiovascular Diabetology
Subjects:
Glucagon-like peptide-1 receptor agonists
Sodium-glucose cotransporter-2 inhibitors
Type 2 diabetes mellitus
Combination therapy
Cardiovascular protection
Online Access:https://doi.org/10.1186/s12933-023-01798-4

Internet

https://doi.org/10.1186/s12933-023-01798-4

Similar Items